Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 46, 2014 - Issue 3
Submit an article Journal homepage
223
Views
11
CrossRef citations to date
0
Altmetric
Case Reports

Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia

Aurélia Henn From the Infectious and Tropical Diseases Department, Paris, FranceCorrespondence[email protected]
,
Guillaume Mellon From the Infectious and Tropical Diseases Department, Paris, France
,
Benoît Henry From the Infectious and Tropical Diseases Department, Paris, France
,
Damien Roos-WeilHematology Department, Groupe Hospitalier Universitaire Pitié Salpêtrière, Université Pierre et Marie Curie–Paris 6, Paris, France
,
Stéphane Jauréguiberry From the Infectious and Tropical Diseases Department, Paris, France
,
Pierre MordantThoracic Surgery Department, Hôpital Européen Georges Pompidou, Université René Descartes–Paris 5, Paris, France
,
Arnaud FekkarMycology and Parasitology Laboratory, Groupe Hospitalier Universitaire Pitié Salpêtrière, Université Pierre et Marie Curie–Paris 6, Paris, France
&
Eric Caumes From the Infectious and Tropical Diseases Department, Paris, France
 show all
Pages 231-234 | Received 26 Oct 2013, Accepted 29 Oct 2013, Published online: 23 Jan 2014

References

  • Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 2013;88:803–16.
  • Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2012;2:CD008078.
  • Gribben JG. How I treat CLL up front. Blood 2010;115: 187–97.
  • Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005; 37:934–6.
  • Silveira FP, Husain S, Kwak EJ, Linden PK, Marcos A, Shapiro R, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis 2007;9:22–7.
  • Walsh R, Ortiz J, Foster P, Palma-Vargas J, Rosenblatt S, Wright F. Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation. Transpl Infect Dis 2008;10:236–9.
  • Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 2009;88:121–32.
  • Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H. Strategies in the management of alemtuzumab- related side effects. Semin Oncol 2006;33(2 Suppl 5): S29–35.
  • Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007;44:204–12.
  • Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16–24.
  • Safdar N, Smith J, Knasinski V, Sherkow C, Herrforth C, Knechtle S, et al. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn Microbiol Infect Dis 2010;66:7–15.
  • Fortún J, Meije Y, Fresco G, Moreno S.[Aspergillosis. Clinical forms and treatment]. Enferm Infecc Microbiol Clin 2012;30:201–8.
  • Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 1998;26:1092–7.
  • Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003;188:305–19.
  • Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002;45:406–7.
  • Colozza C, Posteraro B, Santilli S, De Carolis E, Sanguinetti M, Girmenia C. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies. Int J Antimicrob Agents 2012;39:440–3.
  • Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005;52:15–20.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.